Pfizer Inc. (PFE) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped PFE stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Pfizer Inc. (PFE) demonstrates strong financial health with consistent earnings beat streaks and innovative drug approvals. While facing challenges with negative revenue growth and patent concerns, its high dividend yield, strategic partnerships, and robust pipeline of treatments solidify a bullish long-term outlook. Price projections reflect potential upside supported by these fundamentals. The saved 1-year distribution is P10 $23, P50 $28, and P90 $32.
Last analyzed · Model: gpt-4o
Pfizer Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $23 | Pessimistic plausible scenario |
| P50 | $28 | Median scenario |
| P90 | $32 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Pfizer's strong earnings beat streak, consistent positive EPS surprises, and recent FDA approval for a new Alzheimer's drug indicate robust operational performance and potential upside scenarios. Although facing patent challenges and COVID-19 vaccine sales decline, its dividend yield and collaborations in mRNA research support a favorable outlook.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this PFE analysis generated?
April 26, 2026.
Is this a guaranteed PFE prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full PFE stock analysis · PFE sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.